Comprehensive clinical and molecular portraits of grade 3 ER+ HER-breast cancer

被引：1
|
作者：
Wang, K. [1 ]
Franch-Exposito, S. [2 ]
Li, L. [3 ]
Xiang, T. [4 ]
Wu, J. [3 ]
Ren, G. [4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China
[2] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain
[3] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34P
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [21] Exploring Molecular Portraits Defining Low Grade in Breast Cancer
    Mukherjee, A.
    Russell, R.
    Rueda, O. M.
    Hamarsheh, S.
    Caldas, C.
    Provenzano, E.
    Ellis, I. O.
    JOURNAL OF PATHOLOGY, 2016, 240 : 19 - 19
  • [22] Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer
    Xiaoyan Wu
    Wenchuan Zhang
    Xunxi Lu
    Xiaorong Zhong
    Hong Bu
    Scientific Reports, 14 (1)
  • [23] Clinicopathological differences and survival benefit in ER+/PR+/HER2+vs ER+/PR-/HER2+breast cancer subtypes
    Ding, Wu
    Ye, Dengfeng
    Chen, Haifeng
    Lin, Yingli
    Li, Zhian
    Tu, Chuanjian
    BREAST CANCER, 2024, 31 (02) : 295 - 304
  • [24] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
  • [25] ER+/HER2+breast cancer: are we really de-escalating?
    de Azambuja, E.
    Piccart-Gebhart, M.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 875 - 877
  • [26] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [27] ALT NHEJ is a therapeutic target in hormone therapy resistant ER/PR/HER plus and ER/PR/HER-breast cancers
    Tobin, Lisa A.
    Chumsri, Saranya
    Staats, Paul
    Brodie, Angela
    Tomkinson, Alan
    Rassoo, Feyruz
    CANCER RESEARCH, 2011, 71
  • [28] ER+, HER2-advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
    Chen, Jessica W.
    Jacot, William
    Cortes, Javier
    Krop, Ian E.
    Dent, Susan
    Harbeck, Nadia
    De Laurentiis, Michelino
    Dieras, Veronique
    Im, Young-Hyuck
    Stout, Thomas J.
    Schimmoller, Frauke
    Savage, Heidi M.
    Hutchinson, Katherine E.
    Wilson, Timothy R.
    MOLECULAR ONCOLOGY, 2023, 17 (10) : 2000 - 2016
  • [29] Identification of proteomics-based biomarkers for ER+/HER2-breast cancer stratification: Implications on clinical outcome
    Wang, Guisong
    Shah, Punit
    Searfoss, Rick
    Campbell, J. Leigh Fantacone
    Hooke, Jeffrey A.
    Deyarmin, Brenda
    Zingmark, Rebecca N.
    Somiari, Stella
    Liu, Jianfang
    Kvecher, Leonid
    Sturtz, Lori A.
    Raj-Kumar, Praveen-Kumar
    Granger, Elder
    Vahdat, Linda
    Cutler, Mary L.
    Sarangarajan, Rangaprasad
    Hu, Hai
    Kiebish, Michael A.
    Kovatich, Albert J.
    Narain, Niven R.
    Shriver, Craig D.
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
12345